drugset / Trial / NCT05598112

Effect of Gut Microbiome Intervention on Aging Via Oral FMT

NCT05598112

Phase 0 Recruiting 210 enrolled Chinese Academy of Medical Sciences, Fuwai Hospital
RandomizedParallel-groupQuadruple-blindTreatment

Summary

A severe public health issue facing global population is aging. Increasing preclinical and clinical data indicate the contribution of gut microbiome on aging and aging-related diseases such as cardiovascular disease, Alzheimer Disease, and diabetes. Interventions on microbiota are developed including prebiotics, probiotics, and fecal microbial transplantation (FMT). FMT via oral capsules also advances in recent with limited safety concerns compared with invasive routes. A hypothesis is thus raised that gut microbiome intervention via oral FMT can be a potential safe approach to encourage healthy aging, with multiple aspects evaluated for clinical phenotype of frailty, anthropometric measurement, cognitive function, cardiovascular aging, physical function, living activity, hippocampal volume, telomere length, cognitive biomarkers, inflammatory biomarkers, altered microbial composition and metabolites.

Timeline

Start
2023-04-24
Primary completion
2026-12-31
Completion
2027-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Ornidazole Other / unclassified Oral

Indications

No indication recorded.